EpiCept Corporation To Present At C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

ENGLEWOOD CLIFFS, N.J., July 6 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that Jack Talley, CEO, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 11, 2006 at 10:12 a.m., EDT, at The Mandarin Oriental Hotel, New York, NY. Mr. Talley will present a company overview.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

The presentation will be available via web cast beginning on July 11 for 90 days and can be viewed by clicking on the following link: http://www.wsw.com/webcast/ceut4/epct/

About EpiCept Corporation

EpiCept is an emerging specialty pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The Company has a staged portfolio with several pain therapies in late-stage clinical trials, and a lead oncology compound (for AML) with demonstrated efficacy in a Phase III trial; the compound is intended for commercialization in Europe. EpiCept is based in New Jersey, and the Company's research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of the Company's product candidates, the conduct and results of future clinical trials, the sufficiency of the Company's existing capital resources, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in the Company's periodic reports and other filings with the SEC.

EPCT-GEN

CONTACT: Robert W. Cook of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; or Francesca T. DeVellis of Feinstein Kean Healthcare,+1-617-577-8110, francesca.devellis@fkhealth.com

Web site: http://www.epicept.com/